SCHEMBL555403

SCHEMBL555403

CC(O)CCCOc1ccc(N)cc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.65
TSHR P16473 1/20 0.48
HRH3 Q9Y5N1 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
P2RY12 Q9H244 1/20 0.43
APP P05067 1/20 0.42
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
NFE2L2 Q16236 1/20 0.41
GAA P10253 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6139276 0.91 TDP1 (0.72) TDP1TSHRHRH3NPC1RAB9A
SCHEMBL293649 0.85 TDP1 (0.81) TDP1TSHRNPC1RAB9AKMT2A
SCHEMBL809590 0.80 TDP1 (0.62) TDP1TSHRNPC1RAB9AKMT2A
SCHEMBL18869077 0.80 TDP1 (0.53) TDP1TSHRNPC1RAB9AKMT2A
SCHEMBL9860144 0.79 TDP1 (0.79) TDP1TSHRNPC1RAB9AKMT2A
SCHEMBL6912197 0.79 LMNA (0.64) TDP1TSHRRAB9AALDH1A1MAPT
SCHEMBL2566452 0.79 TDP1 (1.00) TDP1TSHRNPC1RAB9AKMT2A
SCHEMBL27296364 0.78 PARP10 (0.57) HRH3MAPK1GAA
SCHEMBL8755014 0.78 HPGD (0.49) TDP1TSHRHRH3NPC1RAB9A
SCHEMBL7804270 0.78 MEN1 (0.53) HRH3KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105120900-A Compositions and methods for treating chronic inflammation and inflammatory diseases INFIRST HEALTHCARE LTD 2015-12-02 CN claimed
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS BEZWADA BIOMEDICAL, LLC (US) 2009-03-19 US claimed
US-20040147606-A1 SYNERGISTIC MIXTURE OF FUDOSTEINE AND ANALGESICS, ANTIPYRETICS SSP CO., LTD. (JP) 2004-07-29 US claimed
EP-1391201-A1 MEDICINAL COMPOSITIONS SSP Co., Ltd. (JP) 2004-02-25 EP claimed
JP-56115719-A None JP disclosed
EP-4692178-A1 CELLULOSE POWDER AND MOLDED BODY Asahi Kasei Kabushiki Kaisha (JP) 2026-02-11 EP disclosed
US-12427113-B2 Cellulose composition, tablet, and orally disintegrating tablet ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-09-30 US disclosed
WO-2025121315-A1 CELLULOSE POWDER AND MOLDED BODY 旭化成株式会社 2025-06-12 WO disclosed
WO-2025105451-A1 SOLID PREPARATION 第一三共ヘルスケア株式会社 2025-05-22 WO disclosed
WO-2025100523-A1 METHOD FOR PRODUCING SOLID PREPARATION, AND TABLETS 第一三共ヘルスケア株式会社 2025-05-15 WO disclosed
WO-2025100462-A1 SOLID COMPOSITION CONTAINING BROMHEXINE 第一三共ヘルスケア株式会社 2025-05-15 WO disclosed
US-12290602-B2 Cellulose powder, use thereof, and tablets ASAHI KASEI KABUSHIKI KAISHA (JP) 2025-05-06 US disclosed
EP-0631782-B1 Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1999-05-06 EP disclosed
US-5726180-A CAFFEINE, DEXTROMETHORPHAN, PHENYLPROPANOLAMINE, IBUPROFEN TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-03-10 US disclosed
US-5629316-A Stabilized solid pharmaceutical preparation and method of producing the same TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1997-05-13 US disclosed
EP-0475160-B1 Preparation for drug application in minute droplet form IDEA AG (DE) 1996-02-14 EP disclosed
EP-0631782-A1 Stabilized solid pharmaceutical preparation containing dextromethorphan, phenylpropanolamine and caffeine Takeda Chemical Industries, Ltd. (JP) 1995-01-04 EP disclosed
EP-0475160-A1 Preparation for drug application in minute droplet form Cevc, Gregor, Prof. Dr. (DE) 1992-03-18 EP disclosed
WO-1992003122-A1 PREPARATION FOR APPLICATION OF ACTIVE SUBSTANCES IN THE FORM OF MINIMUM-SIZED DROPLETS CEVC GREGOR (DE) 1992-03-05 WO disclosed
JP-S56115719-A ANTIPYRETIC, ANALGESIC, AND ANTIPHLOGISTIC AGENT LION CORP 1981-09-11 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076174-A1 CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS MME, CTSA, ALG1 TDP1 971/4885TSHR 3963/4885HRH3 4704/4885
US-20040147606-A1 SYNERGISTIC MIXTURE OF FUDOSTEINE AND ANALGESICS, ANTIPYRETICS PTGES, CCL11, UROD TDP1 3108/4885TSHR 4617/4885HRH3 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.